<DOC>
	<DOCNO>NCT02511847</DOCNO>
	<brief_summary>[ Background ] : Triple-negative breast cancer ( TNBC ) define lack expression estrogen progesterone receptor well human epidermal growth factor receptor 2 ( HER-2 ) . TNBC characterize distinct molecular , histological unfavorable clinical feature despite high rate response chemotherapy . Based reason , important emergently develop novel therapy and/or treatment strategy increase treatment efficacy survival rate TNBC . [ Rationale ] : Overexpression epidermal growth factor receptor ( EGFR/ErbB1 ) EGFR mutation report TNBC may therefore valid target anti-tumor therapy TNBC . Afatinib ( BIBW 2992 ) ErbB-family blocker irreversibly inhibit signal relevant ErbB-family dimer . Afatinib demonstrate preclinical activity triple-negative breast cancer cell line xenograft model breast cancer , clinical activity phase I study . Based assumption uncontrolled ErbB-signaling directly relate increase oncogenic potential TNBC , study afatinib neoadjuvant treatment TNBC patient important provide novel therapy . [ Aims ] The primary endpoint evaluate pathologic complete response combination afatinib weekly paclitaxel TNBC patient receive neoadjuvant treatment . The secondary endpoint evaluate clinical response safety afatinib without paclitaxel , explore different afatinib-affecting downstream molecular pathway well potential biomarkers predict response afatinib without paclitaxel . [ Patients method ] : Patients TNBC ( clinical T2-T3 , N0-N1 , M0 ; clinical T1-3 , N1-2 , M0 ; T4a tumor ) receive neoadjuvant treatment include open , label , multi-center phase II study . Our schema follow : ( 1 ) Afatinib 40 mg per day 14 day , evaluation , every subject go follow phase matter whether response ( 2 ) follow phase ( combination afatinib paclitaxel ) : Afatinib 40 mg per day , day 1 day 21 , combination paclitaxel 80 mg/m² day 1 , 8 , 15 3-weekly course . In addition clinical assessment , evaluate potential predictive biological marker activity Afatinib without paclitaxel dynamic change molecular maker ( [ serum tissue sample : treatment , 2 week treatment , operation timing ] ; potential molecule , EGFR , EGFR-signaling , FGFR , FGFR-signaling , ERK , p53 , NF-κB , etc . evaluate immunohistochemical stain , mutation analysis , mRNA [ RT-PCR ] , single nucleotide polymorphism analysis , FISH analysis ) . In addition , genetic expression profile compare afatinib-responsive afatinib-unresponsive sample . [ Expected Results ] : The promising clinical activity , tolerable toxicity , potential biomarkers afatinib without paclitaxel TNBC patient receive neoadjuvant setting demonstrate . The result study used conduct large trial would allow u confirm validate hypothesis generate .</brief_summary>
	<brief_title>Trial Afatinib With Paclitaxel Neoadjuvant Therapy TNBC Research Biomarkers Afatinib</brief_title>
	<detailed_description>Objects : Phase II study Primary Objective : To evaluate efficacy combination afatinib weekly paclitaxel assess pathologicalresponse residual tumor . Secondary Objectives : 1 . Efficacy afatinib assess ultrasound breast . 2 . Adverse effect afatinib monotherapy combination afatinib weekly paclitaxel . 3 . Correlation baseline potential biomarkers radiological response afatinib monotherapy . 4 . Correlation down- up-regulation potential biomarkers ( pre-treatment biopsy surgical specimen ) radiological response afatinib paclitaxel . 5 . To identify pharmacodynamic biomarkers , follow translational research carry initial tumor biopsy surgical specimen . 6 . To evaluate dynamic change circulate tumor cell cell-free DNA afatinib monotherapy combination afatinib weekly paclitaxel .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Female patient , age ≥20 year 2 . Histologically confirm invasive ER , PR , HER2negative ( triplenegative ) adenocarcinoma breast 3 . Triplenegative tumor define : . For HER2negative : Fluorescence situ hybridization ( FISH ) negative ( define ratio &lt; 2.0 ) Immunohistochemical ( IHC ) 0 , IHC 1+ , IHC 2+ IHC 3+and FISHnegative ( define ratio &lt; 2.0 ) ii . For ER PRnegative : &lt; 5 % tumor stain immunohistochemistry ( IHC ) 4 . The first TNBC 20 patient without EGFR expression mutation eligible . Interim analysis response rate calculate determine criterion 21 40 patient . 5 . All newly diagnose TNBC patient meet follow criterion : clinical nodepositive T stage patent clinical nodenegative patient cT24 . cT1N0M0 lesion exclude . Patients metastatic disease exclude . The measurement method tumor size physical exam and/or image study . 6 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 01 . 7 . Within 2 week prior randomization : . Adequate bone marrow function , hepatic function , renal function . ii . Controlled blood pressure without antihypertensive treatment iii . Normal prothrombin time ( PT ) partial thromboplastin time ( PTT ) iv . Adequate cardiac function assess 12lead ECG clinically indicate echocardiography document LVEF 8 . Bilateral , synchronous breast cancer allow one primary tumor meet inclusion criterion . 9 . Adequate bone marrow function define WBC ≥3.5 x 109/L , ANC ≥1.5 x 109/L , platelet ≥LLN , hemoglobin ≥10 g/dL . 10 . Adequate liver function define total serum bilirubin ≤1.5X ULN serum transaminase ≤2.5X ULN 11 . Adequate renal function define creatinine ≤1.5X ULN 12 . Able willing give inform consent comply protocol 13 . Written inform consent obtain prior Screening/baseline procedures 14 . Knowledge investigational nature study ability provide consent study participation ; ability willingness comply study visit , treatment , test , study procedure 1 . ER+ ( &gt; 5 % ) PR+ ( &gt; 5 % ) Her2 overexpression 2 . Active second malignancy last five year except non melanomatous skin cancer carcinoma situ cervix . 3 . Prior chemotherapy , radiotherapy target therapy include afatinib Her2 EGFR inhibitor . 4 . Participation another interventional clinical trial precede 30 day prior trial . 5 . Patients concurrent severe and/or uncontrolled medical disease infection could compromise participation study 6 . Prior hypersensitivity reaction taxane Cremophor® EL ( polyoxyethylated castor oil ) 7 . Pregnant breast feeding ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive βHCG laboratory test ( serum &gt; 5 mIU/mL ) 8 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose least 180 day study treatment . Highly effective contraception method include : True abstinence line prefer usual lifestyle subject Female subject male partner sterilization Combination two follow ( a+b a+c , b+c ) : 1 . Use oral , injected implant hormonal method contraception 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : condom male partner occlusive cap 4 . ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository 9 . Patients psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>Afatinib</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Pathologic complete remission</keyword>
</DOC>